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 Introduction 
 Over the last three millennia, civilizations have at-
tempted to cure sickness with products derived from an-
imal, plant and microbial origins or from mineral sourc-
es  [1] . About 80% of the populations of some Asian and 
African countries are estimated to rely on traditional 
medicines as sources for their primary healthcare. An-
nual revenues for herbal medicines in Western Europe 
reached EUR 3.5 billion in 2003–2004  [2] . Although the 
underlying use of many of these so-called natural prod-
ucts clearly lacks scientific logic, several of them never-
theless became founding platforms for modern drug de-
velopment throughout the twentieth century  [1, 3] .
 Three classes of analgesic medications are derived 
from plant ingredients: opiate receptor agonists from 
poppy seeds, cyclooxygenase inhibitors from willow 
bark, and capsaicinoids from chili peppers. Capsaicinoid-
containing preparations are popular natural medicines 
for pain syndromes and although the chili peppers from 
which they are derived ( Capsicum spp.) were originally 
found in the Americas, they are now widespread  [4, 5] . 
Capsaicin of various purities and grades has been widely 
available in pharmacies as low-to-moderate concentra-
tion creams and gels  [5–7] . Increased local perfusion and 
the resulting warming or capsaicin-induced pain leading 
to counterirritation were initially thought to account for 
the analgesic effects of capsaicin  [5] .
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 Abstract 
 Capsaicin has long been used as a traditional medicine to 
treat pain and, recently, its mechanism of analgesic action 
has been discovered. This review article documents the clin-
ical development of capsaicin to demonstrate that pharma-
cognosy still has a profound influence on modern-day drug 
development programs. Capsaicin is a highly selective ago-
nist for the transient receptor potential channel vanilloid-re-
ceptor type 1 (TRPV1), which is expressed on central and pe-
ripheral terminals of nociceptive primary sensory neurons. 
Knockout studies have revealed the importance of TRPV1 as 
a molecular pain integrator and target for novel analgesic 
agents. Topical application of capsaicin at the peripheral ter-
minal of TRPV1-expressing neurons superficially denervates 
the epidermis in humans in a highly selective manner and 
results in hypoalgesia. In three recent randomized controlled 
trials, a patch containing high-concentration capsaicin dem-
onstrated meaningful efficacy and tolerability relative to a 
low-concentration capsaicin control patch in patients with 
peripheral neuropathic pain. Data from clinical practice will 
determine if the high-concentration capsaicin patch is effec-
tive in real-world settings. 
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 Cloning of the capsaicin receptor, i.e. the transient re-
ceptor potential channel of the vanilloid receptor family 
subtype 1 (TRPV1), provided the molecular basis for un-
derstanding the various actions of capsaicin  [8] . TRPV1 
was discovered by an expression cloning strategy utilizing 
capsaicin-induced increases in intracellular calcium con-
centration as a marker. The calcium signal not only indi-
cates opening of a nonselective cation channel and depo-
larization, but also initiation of receptor desensitization 
and downregulation, and degeneration of epidermal nerve 
fibers (ENFs), which is referred to as defunctionalization 
 [5, 9, 10] . As a result of neurite degeneration, ENFs become 
less sensitive to a variety of stimuli (including capsaicin 
itself), leading to reduced pain responses  [5, 10] . A chal-
lenge in capsaicinoid drug development was harnessing 
the desensitizing action of capsaicin without unnecessar-
ily exposing patients to TRPV1 activation-induced pain. 
 An early therapeutic approach using a low-dose cap-
saicin cream formulation to defunctionalize nerve end-
ings in human skin required repeated daily applications 
over weeks  [11] . Although pain arising from such topical 
capsaicin applications is mild, mucous membranes are 
highly sensitive to the effects. Thus, each topical exposure 
to capsaicin can result in irritation of the eyes and respi-
ratory tract  [12] . A systematic review of clinical trials us-
ing low-dose capsaicin creams described moderate-to-
poor efficacy in the treatment of chronic neuropathic 
pain with a number needed to treat of 5.7  [7] . The subop-
timal ratio of defunctionalization to irritation with the 
low-dose capsaicin creams and the lengthy application 
procedure limited their widespread use  [5, 13] .
 Development of structural analogs of capsaicin that 
retained its antinociceptive attributes without inducing 
irritation failed in the late 1980s  [5] . Although the capsa-
icin derivative olvanil was 10 times more potent than cap-
saicin in TRPV1 activation assays and devoid of pungen-
cy, it did not reduce peripheral fiber responsiveness in 
vitro, possibly because of an alternative mechanism of 
receptor activation and desensitization  [5, 14, 15] .
 Initiatives to enhance the clinical effectiveness of cap-
saicin explored use of high doses (10% weight by volume 
[w/v] and weight by weight [w/w] formulations), which 
fully desensitize TRPV1-expressing neurons in human 
skin within a few days or even upon a single application. 
These creams were useful to determine the actions of 
TRPV1 expressing neurons in experimental studies of 
human volunteers  [16, 17] . Whereas pain during applica-
tion is moderate and tolerable in healthy subjects, it may 
be too strong for patients with sensitization or upregula-
tion of TRPV1. Therapeutic use of high-dose creams was 
halted because of severe application site-associated pain 
and the risk of capsaicin contamination to the patient and 
healthcare professional  [16] .
 Recently, a new dermal patch has been developed con-
taining 8% w/w pure  trans -capsaicin in the adhesive layer. 
This formulation, which enables administration of high-
dose capsaicin with a single treatment, is licensed for use 
in peripheral neuropathic pain in nondiabetic adults in the 
European Union and for postherpetic neuralgia (PHN) in 
the USA  [18, 19] . Pretreating the affected area of skin with 
a local anesthetic is advised, although doubts have been 
raised regarding the benefits of such pretreatment  [20, 21] .
 The aim of the current review is to discuss aspects of 
capsaicin pharmacology and advances in this challeng-
ing area of analgesic drug development. After appraising 
the neurophysiological effects and mechanism of analge-
sic action established in preclinical studies, we show that 
the early concepts regarding capsaicin use have been 
translated into clinical application through evidence 
from randomized controlled trials.
 Capsaicin Treatment for Hyperalgesia 
 TRPV1 Receptor 
 Peripheral nociceptive neurons are pseudo-unipolar 
neurons situated in sensory ganglia that have a single 
axon which branches within the ganglion into one pe-
ripheral and one central axon. TRPV1 functions as a 
polymodal receptor on the peripheral terminals of pri-
mary afferent neurons  [22, 23] . On the central terminals, 
TRPV1 may be involved in modulating signal transmis-
sion at the first synapse between the dorsal root ganglion 
or trigeminal ganglion neurons and the dorsal horn or 
caudal spinal trigeminal nucleus neurons  [24–27] .
 TRPV1 is a ligand-gated, nonselective cation channel 
and is one of 30 known members of the TRP ion channel 
family  [8, 28] . TRPV1 is a key receptor involved in the 
transmission and modulation of pain signals  [28] , and is 
an important transducer of noxious stimuli (e.g. heat, low 
pH) and certain chemicals (including capsaicin). TRPV1 
is sensitized by inflammatory mediators responsible for 
inflammatory pain arising from tissue injury  [23, 29] . 
TRPV1 receptor expression increases in some clinical pain 
conditions, possibly resulting from increased retrograde 
transport of nerve growth factor to the cell body  [30, 31] .
 Preclinical Studies Targeting the TRPV1 Receptor 
 Several molecular biology and pharmacological tech-
niques have been employed to elucidate the role of the 
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TRPV1 receptor in somatosensory pathways. Rodents 
lacking the TRPV1 channel are not only insensitive to 
vanilloid-evoked acute pain, but also exhibit impairment 
in their ability to detect thermal stimuli and to develop 
thermal hyperalgesia ( table 1 )  [32–34, 55] . However, re-
sponsiveness to noxious heat stimuli is not completely 
lost in TRPV1 knockout mice. Whereas TRPV1 knock-
out animals lack a component of sensory transduction in 
an otherwise intact neuronal circuit, intrathecal injection 
of capsaicin breaks the connection that all capsaicin-sen-
sitive fibers have with the spinal cord  [37] . It has been 
known for some time that intrathecal administration of 
capsaicin in rats causes long-lasting loss of heat sensitiv-
ity  [35, 36, 56] and can induce selective degeneration of a 
distinct population of primary sensory neurons involved 
in the mediation of chemogenic pain  [57] . More recent 
findings in the mouse indicate that pharmacological ab-
lation of the central branches of TRPV1 nociceptors with 
capsaicin results in a more complete loss of acute sensitiv-
ity to heat pain than that observed in knockout constructs 
( table 1 )  [37] . However, it should be noted that 80–90% of 
neonatal rats desensitized to capsaicin in this way devel-
oped wounds, scabs and areas of alopecia  [58] .
 Interestingly, intrathecal administration of resinifera-
toxin, a more potent agonist of TRPV1 than capsaicin, to 
rats and monkeys not only rapidly inhibits nociceptive 
synaptic transmission but also provides long-lasting an-
algesia in behavioral models (due to destruction of 
TRPV1-expressing central sensory nerve terminals)  [59, 
60] . These data support development of novel analgesics 
targeting TRPV1-expressing neurons either centrally or 
peripherally.
 The striking difference between the limited effects of 
TRPV1 gene knockout and the pronounced effects of ab-
lation of TRPV1-positive neurons on nociceptive signal 
processing is highly relevant for analgesic drug develop-
ment  [61] . While TRPV1 antagonists are anticipated – at 
best – to mimic the effects of TRPV1 knockout, TRPV1-
positive neuron ablation can be mimicked by topical ap-
plication of TRPV1 agonists to target tissues (skin or mu-
cous membranes). 
 Studies in Human Volunteers 
 It is interesting to compare the behavioral effects of 
topical or intradermal capsaicin in humans with the pro-
nounced changes observed in mice after intrathecal in-
jection of capsaicin, as these procedures involve exposure 
to capsaicin at the two terminals of the same neuron. 
Topical exposure to capsaicin in humans leads initially to 
nociceptor firing and a period of enhanced sensitivity to 
painful heat stimuli. A refractory period follows during 
which individuals are relatively resistant to capsaicin and 
heat but not pinprick stimuli  [17, 38, 62, 63] , consistent 
with the existence of a TRPV1-negative population of no-
ciceptors that appear to be specialized for mechanical 
pain. Defunctionalization following continuous capsa-
icin exposure is accomplished via a TRPV1 receptor-me-
diated massive influx of calcium ions into the neuron  [64] 
and the ensuing activation of calcium-sensitive proteases 
(among other mechanisms), which results in reversible 
neurite degeneration that can be visualized as reduction 
in ENFs ( fig. 1 )  [10, 42, 43] . 
1 week after high-dose
topical capsaicin 1 week after control
100 μm
 Fig. 1. Intraepidermal nerve fibers retract following high-dose topical capsaicin treatment. Reprinted from Kennedy et al. [43] with 
permission from Elsevier. 
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 The rate and magnitude of reversible neurite degen-
eration was demonstrated in skin biopsies of healthy vol-
unteers who received either repeated topical applications 
of low-dose capsaicin cream (0.075% w/w) over 7-day and 
3-week treatment periods  [10, 40] or a single application 
of a high-concentration capsaicin patch (8% w/w) for 60 
min  [43] . Overall, the reduction in ENF density was slow-
er and less extensive after repeated application of the low-
concentration capsaicin creams than after a single appli-
cation of the high-concentration capsaicin patch ( table 1 ). 
Sensory testing revealed a pronounced reduction in ther-
mal pain sensitivity but not pinprick sensitivity within 
the first few days after high-dose capsaicin cream  [17, 65] , 
consistent with animal data. One week after application 
of the high-dose patch, however, thermal pain sensitivity 
was normal  [43] , suggesting relatively rapid recovery of 
nociceptive function in healthy subjects. A study using 
laser-evoked potentials and skin biopsies after low-dose 
capsaicin cream treatment also found a more rapid recov-
ery of thermal pain sensation than ENF density  [41] .
 The laser-evoked potential data indicate that heat-sen-
sitive A-fiber nociceptors are also defunctionalized by 
capsaicin, whereas capsaicin was not associated with al-
terations in light touch, deep pain or mechanical pain de-
tection thresholds  [39] . Sharp mechanical (pinprick) pain 
is primarily mediated via capsaicin-insensitive A-fiber 
nociceptors, which would explain why topical capsaicin 
had only modest effects on this stimulus  [17] . In turn, 
these data indicate that painful heat is the most adequate 
stimulus to monitor defunctionalization by capsaicin.
 Therapeutic Use 
 Low-Concentration Topical Capsaicin 
 Despite promising pharmacodynamic data describing 
hypoalgesia accompanied by ENF degeneration in hu-
man volunteers  [10] , low-concentration capsaicin creams 
( ^  0.1%) have demonstrated poor-to-modest efficacy in 
neuropathic pain syndromes over the short term ( table 1 ) 
 [44–49] . Explanations for the disappointing results in-
clude the low concentration of pure capsaicin used and 
poor patient adherence  [9, 66–68] . 
 High-Concentration Topical Capsaicin 
 High-concentration capsaicin was first used as a 10% 
w/v solution in 10 patients with intractable pain due to 
bilateral peripheral neuropathy but this approach was 
terminated due to severe pain on application (despite re-
gional analgesia) and risk of aerosol contamination  [16] . 
More recently, a dermal patch has been developed con-
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saicin (8% w/w) in the adhesive layer (QUTENZA TM ; 
NGX-4010). Advances in stereoselective medicinal chem-
istry have facilitated synthesis of pure  trans -capsaicin 
(99%), which is identical to the naturally occurring mol-
ecule  [9, 67] . The synthetic process delivers higher con-
centrations of active  trans -capsaicin than can be extract-
ed from capsicums  [67] . The high-concentration patch 
demonstrated efficacy in patients with PHN and in those 
with HIV-associated distal sensory polyneuropathy 
(HIV-DSP) ( table 1 )  [51–54] . Lack of unnecessary expo-
sure to capsaicin during the application and removal pro-
cedure represents a practical tolerability advantage of the 
patch over capsaicin creams. In addition, only one treat-
ment is required every 3 months (or longer depending on 
pain control status).
 In contrast to the clinical trial data for low-concentra-
tion capsaicin creams, the clinical efficacy data for the 8% 
capsaicin patch are entirely consistent with skin biopsy 
data. In double-blind randomized trials that used a low-
dose capsaicin patch (0.04% w/w) as an active control to 
maintain blinding, a single application of the 8% capsa-
icin patch produced rapid and prolonged pain relief in 
patients with moderate-to-severe PHN or HIV-DSP, ir-
respective of whether they were receiving concomitant 
medications for neuropathic pain ( table 1 )  [51–53] .
 A 60-min application of the 8% capsaicin patch – 
shown to be effective in patients with PHN  [50] – exerted 
its maximum therapeutic effect as early as 2 days after 
application  [51] . Significantly more patients treated with 
the 8% capsaicin patch reported a  6 30% pain decrease 
from baseline than control patients (42 vs. 32%; p =  0.04) 
 [51] . Furthermore, the proportion of patients reporting 
an improvement on the Patient Global Impression of 
Change scale was significantly higher among those treat-
ed with the 8% capsaicin patch compared with those 
treated with the control at both week 8 (53 vs. 42%; p = 
0.03) and week 12 (55 vs. 43%; p = 0.04)  [51] . Similarly, a 
dose-finding study in patients with HIV-DSP revealed 
that a single 30- or 120-min (but not 60-min) application 
of the 8% capsaicin patch provided meaningful pain relief 
within 2 weeks, which persisted throughout the 12-week 
observation period  [53] . The proportion of patients who 
reported a  6 30% pain decrease from baseline was  1 2-
fold greater in the group treated with the 8% capsaicin 
patch than the control group (42 vs. 18%; p = 0.01)  [53] . 
The importance of these positive trial data cannot be un-
derstated as there are very few, if any, other treatments 
with proven effectiveness in HIV-DSP  [69] . Two open-
label studies, which followed patients for a total of 48 
weeks after their first treatment, have shown that re-ap-
plication of the 8% capsaicin patch results in reproducible 
tolerability and safety, and suggest that a comparable de-
gree of pain relief can be achieved with each retreatment 
( table 1 )  [52, 54] . 
 The clinical efficacy of the 8% capsaicin patch for 
treatment of PHN and HIV-DSP has been confirmed in 
two independent meta-analyses  [70, 71] and the Europe-
an Federation of Neurological Societies have included the 
8% capsaicin patch in recent guidelines on the pharma-
cological treatment of neuropathic pain  [69] . Further 
studies are now needed to identify those patients who get 
the most pain relief and to identify other peripheral neu-
ropathic pain syndromes that may respond to treatment 
with the 8% capsaicin patch. Patients with heat hyperal-
gesia, who make up about 18% of patients with neuro-
pathic pain  [72] , are likely candidates. 
 Capsaicin Safety 
 Intradermal capsaicin administration leads to irre-
versible loss of TRPV1 neurons due to systemic distribu-
tion in newborn rodents  [73, 74] , and to transient TRPV1 
denervation at the injection site in human adults  [75] . Re-
peated, long-term application of topical capsaicin to the 
rat hind paw did not damage the sciatic nerve or result in 
neuron loss in the dorsal root ganglion  [76] .
 High-level dietary intake of capsaicin is not associated 
with any safety concerns in humans. The estimated high-
est capsaicin dietary exposure (in India, Mexico and 
Thailand) is 25–200 mg/day  [77] and the total capsaicin 
content of one 8% capsaicin patch is within that range 
(179 mg per patch, of which only a fraction is absorbed). 
Systemic absorption of capsaicin is very low following a 
60- or 90-min application of the 8% capsaicin patch, with 
a maximum plasma concentration of 17.8 ng/ml observed 
in any patient  [78] . Systemic exposure to capsaicin follow-
ing 8% capsaicin patch application is also transient as 
capsaicin levels decline rapidly with a mean population 
elimination half-life of 1.6 h. Furthermore, detectable lev-
els of capsaicin metabolites were not observed in any pa-
tients. Therefore, treatment with the 8% capsaicin patch 
is unlikely to result in systemic side effects or to alter the 
systemic metabolism of concomitant medications. In 
clinical trials, topical application of capsaicin was gener-
ally well tolerated and associated with transient applica-
tion-site reactions such as pain and erythema ( table 1 ).
 It is important to evaluate the safety of topical capsa-
icin in patients with diabetes as they likely have ongoing 
neurodegenerative processes that might be exacerbated 
by capsaicin. Case-control data indicate that ENF regen-
eration after low-dose capsaicin is slower among patients 
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 Discussion 
 A better understanding of the molecular and cellular 
effects of capsaicin has helped rationalize the popularity 
of this molecule as a means of assuaging pain. Theories 
on the mechanism of action of capsaicin have shifted 
from increased perfusion and counterirritation to de-
functionalization. Defunctionalization of the entire pop-
ulation of TRPV1-expressing neurons is more efficient in 
reducing pain behavior in animals than knockout of 
TRPV1. Likewise in humans, defunctionalization by 
high-dose patches has been found effective in meta-anal-
yses of clinical trials, whereas TRPV1-antagonists have 
yet to be approved (they are also burdened by adverse ef-
fects such as fever, hypertension and gastric ulceration 
 [29] ). Both low-dose and high-dose topical capsaicin are 
listed as effective in the most recent meta-analysis on 
neuropathic pain therapy  [71] . Of all the effective thera-
pies, the high-dose patch is unique in that it can deliver 
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tivation of TRPV1 by topical application of the 8% capsa-
icin patch translated into meaningful pain relief from 
PHN and HIV-DSP.
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study describing how pharmacognosy can provide valu-
able and necessary inputs into rational drug design, and 
how medicinal chemistry and neurobiology can improve 
traditional medicines. For the capsaicin patch, the diffi-
cult step of translating efficacy in defunctionalizing no-
ciceptive neurons in animal models to pain relief in hu-
man patients was greatly facilitated by pre-existing clini-
cal experience with topical capsaicin preparations that 
had been in use before the understanding of its molecular 
basis of action.
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